louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04743427: EFFECTS OF BODY-BLADE EXERCISES ON NECK POSTURE, FUNCTION, AND MUSCLE STRENGTH IN FORWARD HEAD POSTURE
Official title: EFFECTS OF BODY-BLADE EXERCISES ON NECK POSTURE, FUNCTION, AND MUSCLE STRENGTH IN FORWARD HEAD POSTURE
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Forward Head Posture
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-02-08
Enrollment: 42
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double-Blinded Randomized Controlled Trial (one investigator to make the assessment,and another investigator for application of the treatment procedures)
Primary purpose: TREATMENT

Brief summary: This study will be conducted to determine the effect of adding Body-blade exercises to traditional treatment on posture, scapular muscles strength, neck pain, and function in individuals with forward head posture

Detailed description: Many studies have proposed that the Body-blade may be a more effective tool for activating the muscles employed during the training and rehabilitation of the shoulder and trunk than traditional interventions such as cuff weights and Therabands. There is few literature which studied the effect of Body-blade exercises on neck problems. So there is insufficient evidence for their effectiveness on improving forward head posture.

Eligibility criteria: Inclusion Criteria :

1. Participants with FHP of both genders
2. Age range from 20-40 years
3. craniovertebral angle (CVA) less than 52 degrees

Exclusion Criteria :

1. Patients with a previous diagnosis of a musculoskeletal system disease over the last 6 months,
2. severely unstable spine
3. osteoporosis
4. vascular disease
5. cervical or shoulder neurological movement disorder

Primary outcomes:
measure: cranio vertebral angle using the Autocad
timeFrame: 5 minutes
Secondary outcomes:
measure: pain using visual Analogue Scale (VAS)
timeFrame: 5 minutes
measure: Neck function using the Neck Disability Index
timeFrame: 5 minutes
measure: Scapular muscles strength using Hand Held Dynamometer
timeFrame: 10 minutes
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Mansheyet El Bakry General Hospital
Study officials:
References:
citation: Sheikhhoseini R, Shahrbanian S, Sayyadi P, O'Sullivan K. Effectiveness of Therapeutic Exercise on Forward Head Posture: A Systematic Review and Meta-analysis. J Manipulative Physiol Ther. 2018 Jul-Aug;41(6):530-539. doi: 10.1016/j.jmpt.2018.02.002. Epub 2018 Aug 11.
citation: Lister JL, Del Rossi G, Ma F, Stoutenberg M, Adams JB, Tobkin S, Signorile JF. Scapular stabilizer activity during Bodyblade, cuff weights, and Thera-Band use. J Sport Rehabil. 2007 Feb;16(1):50-67. doi: 10.1123/jsr.16.1.50.
Clinical trial NCT00357227: Atrial Fibrillation and the Risk for Neurological Complications
Official title: Atrial Fibrillation and the Risk for Neurological Complications
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation
Stroke
Vascular Dementia
Mild Cognitive Impairment
Lead sponsor: University Hospital Muenster
Sponsor class: OTHER
Collaborators: name: German Federal Ministry of Education and Research
First posted: 2006-07-27
Enrollment: 1000
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: B8: Atrial fibrillation and the risk of neurological complications

Twenty-five thousand acute strokes are caused by atrial fibrillation every year. But even more frequent than symptomatic strokes are silent infarctions of the brain. Silent strokes remain undetected in most cases, but cumulate over time and progressively impair cognition. The impact of atrial fibrillation on subacute brain infarctions is not yet known. Moreover, it has not been elucidated so far how effective different therapeutic strategies in the treatment of atrial fibrillation prevent cognitive impairment. Thus, this study aims at evaluating the influence of different types of atrial fibrillation on silent strokes and the related impairment in cognitive functions. Other risk factors and cardiovascular diseases that are known to provoke the development of strokes will be assessed as well. So, it will be possible to isolate the contribution of atrial fibrillation to silent strokes and related cognitive impairment in segregation to other relevant factors. AF patients and controls will be examined twice in two years in order to evaluate the role of atrial fibrillation and differential therapeutic interventions with regard to the progression of silent strokes and cognitive impairment in a within subject-design.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of permanent, paroxysmal or episodic atrial fibrillation in the past or at present

Exclusion Criteria:

* Pacemaker
* Metal implants
* History of acute stroke
* Diagnosis of vascular or degenerative dementia
* History of brain tumors
* History of severe brain injury
* History of psychiatric disorders
* Pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Münster
country: Germany
facility: University Hospital Münster, Dept. of Neurology
state: NRW
Study officials:
affiliation: University Hospital Münster, Department of Neurology
name: Stefan Knecht, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00094627: Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)
Official title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Adult Patients With Primary Insomnia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Primary Insomnia
Lead sponsor: H. Lundbeck A/S
Sponsor class: INDUSTRY
First posted: 2004-10-22
Enrollment: 465
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to test the safety and effectiveness of the Investigational Drug on insomnia.


Eligibility criteria: Inclusion Criteria:

* Adult patients with a diagnosis of primary insomnia and in good physical and mental health

Exclusion Criteria:

* Adult patients with other medical , neurological and sleep disorders

Primary outcomes:
measure: Amount of time spent awake and time to fall asleep at night after 2 days
timeFrame: After 2 days
Secondary outcomes:
measure: Amount of time spent awake and time to fall asleep at night after 30 days
timeFrame: After 30 days
measure: Amount of deep sleep after 2 days
timeFrame: After 2 days
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Lankford DA, Corser BC, Zheng YP, Li Z, Snavely DB, Lines CR, Deacon S. Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies. Sleep. 2008 Oct;31(10):1359-70.
citation: Svetnik V, Snyder ES, Tao P, Roth T, Lines C, Herring WJ. How well can a large number of polysomnography sleep measures predict subjective sleep quality in insomnia patients? Sleep Med. 2020 Mar;67:137-146. doi: 10.1016/j.sleep.2019.08.020. Epub 2019 Sep 11.
Clinical trial NCT01220427: Micro-RNA Expression Profiles in High Risk Prostate Cancer
Official title: Micro-RNA Expression Profiles in High Risk Prostate Cancer
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Prostate Cancer
Radical Prostatectomy
Keywords: high-risk prostate cancer
radical prostatectomy
micro-RNA
Lead sponsor: Wuerzburg University Hospital
Sponsor class: OTHER
Collaborators: name: Universitaire Ziekenhuizen KU Leuven
First posted: 2010-10-13
Enrollment: 300
Sex: MALE
Minimum age (years): 35
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: University hospital, community hospital

Brief summary: The purpose of this study is to determine whether specific Micro-RNA expression profiles are related to Prostate cancer outcome.


Eligibility criteria: Inclusion Criteria:

Patients with clinically localised high risk prostate cancer (cT\>2, bx GS \>7, PSA \>20 ng/ml) scheduled for radical prostatectomy.

Exclusion Criteria:

Non high risk prostate cancer

Primary outcomes:
measure: Recurrence free survival
timeFrame: Yearly update until clinical progression
Secondary outcomes:
measure: Cancer specific survival
timeFrame: Yearly update until death
Other outcomes:
Locations:
city: Würzburg
country: Germany
facility: Department of Urology and Pediatric Urology University Hospital Würzburg
Study officials:
References:
Clinical trial NCT04027127: The Role of Netrin -1 in Acute Coronary Syndrome
Official title: The Effect of Serum Netrin-1 Levels on Diagnosis and Prognosis in Patients Presenting to the Emergency Department With Acute Coronary Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Coronary Syndrome
Keywords: netrin-1
acs
reperfuzion
Lead sponsor: Aksaray University Training and Research Hospital
Sponsor class: OTHER
First posted: 2019-07-19
Enrollment: 238
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: PATIENT AND CONTROL GROUP will be divided into two.
Primary purpose: DIAGNOSTIC

Brief summary: In our study, Netrin -1; We found that patients with ACS increased at the time of admission, decreased TIMI 3 flow after angiography, and higher risk groups in high risk groups such as TIMI and GRACE were found to have higher Netrin-1 levels.


Eligibility criteria: Inclusion Criteria:

* Patients over the age of 18
* diagnose ACS
* patients undergoing angiography

Exclusion Criteria:

* CVE history
* Neurological disease
* Pregnancy and Lactation
* Liver failure
* Diagnosed malignity
* Use of anticonvulsant and nephrotoxic medication
* Chronic kidney disease
* Not having angiography
* Developing acute renal failure after angiography
* Patients who rejected to participate were excluded.

Primary outcomes:
measure: serum netrin-1 value
timeFrame: 30 minute
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Aksaray/Turkey
name: Hüseyin Mutlu, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00131027: High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
Official title: Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Lymphoblastic Leukemia, Acute
Keywords: acute lymphoblastic leukemia
newly diagnosed
BCR-ABL-negative
Lead sponsor: Japan Adult Leukemia Study Group
Sponsor class: OTHER
First posted: 2005-08-17
Enrollment: 240
Sex: ALL
Minimum age (years): 25
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the clinical efficacy of high-dose methotrexate consolidation therapy for adult patients with BCR-ABL-negative ALL.

Detailed description: Although the multi-agent chemotherapies in current use produce complete remission for a majority of patients with acute lymphoblastic leukemia (ALL), the prognosis for adult ALL remains discouraging due to a high incidence of relapse. Optimal post-remission therapy, therefore, has been a matter of vital concern. In some pediatric ALL studies, the use of high-dose methotrexate (MTX) as a consolidation therapy, has been shown to improve outcome, however, there has been no randomized controlled trials to test its clinical efficacy in adult ALL. With this concern, the Japan Adult Leukemia Study Group (JALSG) has planned a prospective randomized controlled trial comparing high-dose MTX and intermediate-dose MTX for ALL patients who are negative for BCR-ABL. Those who are positive for BCR-ABL can participate in a separate protocol.

Eligibility criteria: Inclusion Criteria:

* Previously untreated BCR-ABL-negative ALL
* Age between 25 and 64 years
* Performance status between 0 and 3 (ECOG criteria)
* Adequate functioning of the liver (serum bilirubin level \< 2.0 mg/dL); kidneys (serum creatinine level \< 2.0 mg/dL); and heart (left ventricular ejection fraction greater than 50% and no severe abnormalities detected on electrocardiograms and echocardiographs).
* Written informed consent to participate in the trial

Exclusion Criteria:

* Uncontrolled active infection
* Another severe and/or life-threatening disease
* Positive for HIV antibody and/or hepatitis B surface (HBs) antigen tests
* Another primary malignancy which is clinically active and/or requires medical interventions
* Pregnant and/or lactating women
* Past history of renal failure

Primary outcomes:
measure: Disease-free survival
timeFrame: 3 years
Secondary outcomes:
measure: Toxicity
timeFrame: 2 years
measure: The rate of complete remission
timeFrame: 2 months
Other outcomes:
Locations:
city: Nagoya
country: Japan
facility: Department of Hematology, Nagoya University Graduate School of Medicine
Study officials:
affiliation: Nagoya University
name: Fumihiko Hayakawa, MD
role: STUDY_DIRECTOR
affiliation: Nagoya University
name: Tomoki Naoe, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01390727: Effects of Slow Breathing on Blood Pressure and Autonomic Function
Official title: Effects of Slow Breathing on Blood Pressure and Autonomic Function in Hypertensive Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Keywords: hypertension
device-guided breathing
autonomic function
Resperate
Lead sponsor: Fundação de Amparo à Pesquisa do Estado de São Paulo
Sponsor class: OTHER_GOV
First posted: 2011-07-11
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypertension is a chronic disease that affects about 23% of the brazilian population. The treatment of hypertension by pharmacological intervention is efficacious, but has side effects and significant costs. Techniques that reduce the respiratory rate are shown as a effective non-pharmacological treatment in controlling blood pressure. Evidence has shown that a slow and deep breathing rate, around 10 breaths per minute or less, significantly reduces blood pressure. However, the physiological mechanisms involved in blood pressure decrease due to decreased respiratory rate are not yet known. Therefore the goals of this study will evaluate the chronic effect of breathing exercise guided on office and 24 hours blood pressure and analyse the chronic effect of breathing exercise guided over the autonomic function in hypertensive patients in stages 1 and 2.


Eligibility criteria: Inclusion Criteria:

* Hypertensive patients with or without use of antihypertensive drug therapy with office systolic blood pressure between 140 and 179 mmHg and / or office diastolic between 90 and 109mmHg).
* Adults over 18 years.
* Both genders.

Exclusion Criteria:

* Use of medications that alter sympathetic nerve activity (beta blockers and / or sympatholytics).
* Use of three or more classes of antihypertensive drugs
* Secondary Hypertension
* Chronic Respiratory Disease
* Diabetes Mellitus.
* Chronic Kidney Disease with Clearance Creatinine \<60 ml/min
* Congestive heart failure
* Coronary disease
* Pregnant
* BMI \> 30 kg/m2

Primary outcomes:
measure: blood pressure reduction
timeFrame: 8 weeks after the randomization
Secondary outcomes:
measure: autonomic regulation
timeFrame: 8 weeks after randomization
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: General Hospital of School of Medicine - Universiy of Sao Paulo
state: SP
Study officials:
affiliation: General Hospital of School of Medicine - University of Sao Paulo
name: Decio Mion Junior, MD
role: STUDY_CHAIR
References:
citation: de Barros S, da Silva GV, de Gusmao JL, de Araujo TG, de Souza DR, Cardoso CG Jr, Oneda B, Mion D Jr. Effects of long term device-guided slow breathing on sympathetic nervous activity in hypertensive patients: a randomized open-label clinical trial. Blood Press. 2017 Dec;26(6):359-365. doi: 10.1080/08037051.2017.1357109. Epub 2017 Jul 20.
Clinical trial NCT02970227: Inflammatory Cardiomyopathy Baseline Cohort (SFB/TR19)
Official title: Inflammatory Cardiomyopathy Cohort of the SFB/TR19 [Kohorte "Entzündliche Kardiomyopathien" Des Sonderforschungsbereichs/Transregio 19 (SFB/TR19)]
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiomyopathies
Heart Failure
Keywords: heart failure
cardiomyopathies
myocarditis
Lead sponsor: University Medicine Greifswald
Sponsor class: OTHER
First posted: 2016-11-21
Enrollment: 920
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with suspected or validated inflammatory cardiomyopathy at baseline

Brief summary: cohort of cardiomyopathy patients (suspected or validated inflammatory cardiomyopathy) recruited at baseline by the SFB-TR19 project. Standardized protocols used for the assessment of medical history and examinations, laboratory biomarkers, and the collection of various biosamples for biobanking purposes.


Eligibility criteria: Inclusion Criteria:

* suspected inflammatory cardiomyopathy at baseline

Exclusion Criteria:

* none

Primary outcomes:
measure: Cardiovascular events
timeFrame: 1-year follow-ups
Secondary outcomes:
measure: LVEF
timeFrame: 1-year follow-ups
measure: VO2peak
timeFrame: 1-year follow-ups
measure: QOL
timeFrame: 1-year follow-ups
measure: Mortality
timeFrame: 1-year follow-ups
Other outcomes:
Locations:
city: Greifswald
country: Germany
facility: Department of Internal Medicine B, University Medicine Greifswald
state: MV
Study officials:
References:
Clinical trial NCT04086927: Unna Boots for Ankle Fracture Swelling
Official title: Unna Boot: a Technique to Decrease Preoperative Soft Tissue Swelling Following Ankle Fractures
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Ankle Fractures
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
First posted: 2019-09-12
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the difference in soft tissue swelling prior to surgery and wound complications after surgery between unna boot application versus standard splint application. An unna boot is an extra zinc covered wrap around your leg followed by standard splint application (cotton dressing, plaster, then soft dressing). Prior to surgery the participant's swelling will be measured and compared to the standard splint application group. After surgery, the participant will be monitored for wound complications, pain, and range of motion.

Detailed description: The purpose of this study is to compare preoperative swelling and frequency of wound complications in ankle fractures through standard splint and an unna boot compressive dressing with a splint. Quantitative and qualitative measurements will be analyzed to compare edema and wound complications. Secondary goals are to evaluate the quantitative differences in ankle range of motion and visual analogue scale (VAS) pain scores. The hypothesis of this proposed study is that there will be less soft tissue swelling and wound complications with the use of an unna boot when compared to the standard splint. The investigators also hypothesize that there will be improved ankle range of motion and visual analogue scale (VAS) pain scores with the use of an unna boot when compared to a standard splint. Participants will be randomized to either the standard splint or an unna boot and quantitative and qualitative measures will be collected. This data could change the practice for preoperative management of soft tissue swelling following ankle fractures.

Eligibility criteria: Inclusion Criteria:

* acute ankle fracture

Exclusion Criteria:

* low energy ankle fracture
* open ankle fracture
* unwillingness to participate
* allergy to zinc
* revision surgery

Primary outcomes:
measure: Baseline swelling using Figure-8 Measurement
timeFrame: Baseline (Initial encounter)
measure: Mean swelling using Figure-8 Measurement
timeFrame: 6 weeks follow up visit
measure: Mean pain scores on visual analogue scale at initial encounter
timeFrame: Baseline (initial encounter)
measure: Mean pain scores on visual analogue scale at 6 week follow up visit
timeFrame: 6 weeks follow up visit
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Orthopaedic Surgeon
name: Christopher E Gross, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01427127: Effect of Ramosetron on Bowel Motility After Colorectal Resection
Official title: Effect of Ramosetron on Bowel Motility and PONV After Laparoscopic Stomach and Colorectal Resection
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Postoperative Nausea and Vomiting
Lead sponsor: Kyunghee University Medical Center
Sponsor class: OTHER
First posted: 2011-09-01
Enrollment: 64
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Ramosetron is effective in preventing postoperative nausea and vomiting. Several studies reported that ramosetron is also effective treatment diarrhea-predominant irritable bowel syndrome. The investigators examine the effect of ramosetron used for preventing postoperative nausea and vomiting on bowel motility.

Detailed description: Ramosetron, a new potent and long-acting selective 5-HT3 receptor antagonist, is effective for preventing postoperative nausea and vomiting. Also several studies reported that ramosetron is effective treatment of irritable bowel syndrome because it inhibits the accelerated colonic transit, abnormal colonic water transport, defecation abnormality, and the lowered colonic perceptual threshold by corticotrophin-releasing hormone. There is no study about the effect of ramosetron used for preventing postoperative nausea and vomiting on postoperative bowel motility. In this study, the investigators examine the effect of ramosetron on postoperative bowel motility.

Eligibility criteria: Inclusion Criteria:

* 20-70 yr of age,
* ASA I or II,
* scheduled for laparoscopic colorectal surgery

Exclusion Criteria:

* antiemetic use within 24hr prior to surgery
* steroid use within 24hr prior to surgery or 48hr after surgery
* insulin dependent DM
* cardiovascular or pulmonary disease
* renal or hepatic insufficiency
* BMI \>=35kg/m2
* pregnancy

Primary outcomes:
measure: time from surgery to passage of gas
timeFrame: within 10days after surgery
measure: time from surgery to defecation
timeFrame: within 10 days after surgery
Secondary outcomes:
measure: incidence and severity of postoperative nausea and vomiting
timeFrame: 0 - 6 hours, 6-24 hours, and 24-48 hours after surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: School of Medicine, Kyung Hee University
Study officials:
affiliation: School of Medicine, Kyung Hee University
name: Mi Kyeong Kim
role: PRINCIPAL_INVESTIGATOR
References: